Publicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (32)

2024

  1. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021) (Clinical and Translational Oncology, (2022), 24, 4, (646-657), 10.1007/s12094-022-02816-9)

    Clinical and Translational Oncology

  3. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 646-657

2021

  1. Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

    Health and Quality of Life Outcomes, Vol. 19, Núm. 1

2020

  1. The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

    Expert Opinion on Biological Therapy, Vol. 20, Núm. 1, pp. 15-22

2019

  1. Management and supportive treatment of frail patients with metastatic pancreatic cancer

    Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404

  2. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

    International Journal of Cancer, Vol. 143, Núm. 8, pp. 1954-1962

2017

  1. Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients

    Journal of the National Cancer Institute, Vol. 109, Núm. 4

2016

  1. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

    Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22

  2. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

    Annals of Oncology, Vol. 27, pp. vi213

2015

  1. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: Clinical and biological features

    BMC Cancer, Vol. 15, Núm. 1

  2. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589

  3. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial

    Journal of the National Cancer Institute, Vol. 107, Núm. 2

  4. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

  5. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

  6. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 942-953

  2. Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

    Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178